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Abstract
Replication-defective adenovirus type 5 (Ad5) vector-based vaccines are widely known to induce strong immunity against immunodeficiency
viruses. To exploit this immunogenicity while overcoming the potential problem of preexisting immunity against human adenoviruses type 5, we
developed a recombinant chimeric adenovirus type 5 with type 35 fiber vector (rAd5/35). We initially produced a simian immunodeficiency virus
(SIV) gag DNA plasmid (rDNA-Gag), a human immunodeficiency virus type 1 (HIV-1) 89.6 env DNA plasmid (rDNA-Env) and a recombinant
Ad5/35 vector encoding the SIV gag and HIV env gene (rAd5/35-Gag and rAd5/35-Env). Prime-boost vaccination with rDNA-Gag and -Env
followed by high doses of rAd5/35-Gag and -Env elicited higher levels of cellular immune responses than did rDNAs or rAd5/35s alone. When
challengedwith a pathogenic simian human immunodeficiency virus (SHIV), animals receiving a prime-boost regimen or rAd5/35s alonemaintained
a higher number of CD4+ T cells and remarkably suppressed plasma viral RNA loads. These findings suggest the clinical promise of an rAd5/35
vector-based vaccine.
© 2007 Elsevier Inc. All rights reserved.Keywords: DNA vaccine; Recombinant Ad5/35; Cellular immunity; Pathogenic SHIV challengeIntroduction
HIV-specific cellular and humoral responses play a critical
role in controlling viral replication and disease progression
(Mascola, 2003; Letvin et al., 2002; Musey et al., 1997). It has
been reported that recombinant live virus- and bacteria-based
vaccines such as recombinant adenovirus (Mascola et al., 2005;
Shiver et al., 2002) recombinant poxvirus (Someya et al., 2004;
Amara et al., 2001), and recombinant BCG (Ami et al., 2005;
Someya et al., 2005) elicited high levels of effective immunity⁎ Corresponding author. Department of Virology III, National Institute of
Infectious Diseases 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan.
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doi:10.1016/j.virol.2007.06.012against immunodeficiency viruses when used either alone or in
conjunction with other vectors.
Adenoviruses, which are associated with benign pathologies
in humans, are attractive for use in HIV vaccines because their
genome has been extensively studied and because methods for
constructing recombinant vectors with them are well established
(Imler, 1995). A regimen that primes with DNA and then boosts
with rAd5 is known to protect macaques against SHIV challenge
by inducing high levels of viral-specific immunities (Shiver
et al., 2002). However, Ad5 has been prevented from fully
realizing its clinical potential (Catanzaro et al., 2006) because of
preexisting humoral immunity to adenoviruses (Barouch et al.,
2004; Casimiro et al., 2003). A previous study demonstrated that
neutralizing antibodies against Ad5 are widespread in healthy
blood donors in the developed world, whereas neutralizing
391K. Someya et al. / Virology 367 (2007) 390–397antibodies against Ad35 are rare (Kostense et al., 2004; Vogels et
al., 2003). Furthermore, patients at risk of AIDSwere reported to
have a much higher seroprevalence of Ad5 than Ad35 (Kostense
et al., 2004).
We have recently constructed an adenovirus serotype 5 vector
that possesses serotype 35 fiber (rAd5/35) that encodes the
simian immunodeficiency virus (SIV) gag gene or human
immunodeficiency virus type 1 (HIV-1) IIIB env gp160 gene
(Xin et al., 2005). The rAd5/35 vector, which lacks the E1 and
E3 genes that are responsible for viral replication (Imler, 1995),
interacts with CD46-expressing cells (Gaggar et al., 2003) and
antigen-presenting cells (Rea et al., 2001). The rAd5/35 vector
was shown to enter human dendritic cells (DC) more efficiently
than Ad5 and activate T cells ex vivo (Ophorst et al., 2004),
suggesting that a rAd5/35 vector-based vaccine may be an
effective activator for T cell immunity. However, rAd5/35
vector-expressing measles virus hemagglutinin was less immu-
nogenic than rAd5 in low-dose immunization in macaques and
suggested that fiber exchange may not circumvent anti-Ad5
immunity during acute Ad5 infection in mice (Ophorst et al.,
2004).
Recently, hyper variable regions on the Ad5 hexon protein
were successfully replaced with those of the rare Ad48, allowing
preexisting anti-vector immunity to be circumvented (Roberts et
al., 2006). We previously showed that, when combined with
plasmid DNA, the rAd5/35 vector elicited high levels of cellular
responses that in turn protected mice from challenge with a
virulent vaccinia virus encoding HIV-1 BH8 env (Xin et al.,
2005). Furthermore, the rAd5/35 vector-based vaccine was not
affected by the preexisting anti-Ad5 immunity in mice.
These results suggest that a vaccine combining plasmid DNA
and the rAd5/35 vector may induce effective viral-specific
immunities in macaques. In this study, we determined the
vaccine efficacy of relatively high doses of rAd5/35 vector-
based HIV vaccine in an SHIV macaque model.
Results
Vaccine-induced T cell responses to SIV Gag and HIV Env
After priming with rDNA-Gag and rDNA-Env, Gag- and
Env-specific IFN-γ spot-forming cells (SFC) were detected in
both the rDNA and the prime-boost groups (Fig. 1A). The
numbers of SFC against Gag peaked at 16 weeks in the rDNA
and the prime-boost groups, with numbers averaging 120 in the
rDNA group and 128 in the prime-boost group. ELISPOT
responses to Env also peaked at 16 weeks, with average numbers
of 33 in the rDNA group and of 66 in the prime-boost group.
Gag- and Env-specific ELISPOT responses were not observed in
animals immunized with cDNA (SFC ≤10).
Two serial high-dose injections with rAd5/35-Gag and rAd5/
35-Env per animal dramatically augmented Gag- and Env-
specific ELISPOT responses in the prime-boost group (Fig. 1A).
At Week 150, the prime-boost group averaged 53 Gag-specific
and 35 Env-specific SFC. Two weeks after the two serial
injections with rAd5/35 (154 weeks), the average number of
Gag-specific SFC increased to 1073 and that of Env-specificSFC to 340. Two serial injections with rAd5/35s also elicited
higher ELISPOT responses in the rAd5/35 group (Fig. 1A), with
the average number of Gag-specific SFC increasing from 35 to
570 and that of Env-specific SFC, from 15 to 165. The levels of
both Gag and Env ELISPOT responses at the time of virus
challenge (154 weeks) significantly increased in the prime-boost
group, and they were higher than those in the rDNA (Gag,
pb0.01; ENV, pb0.01) and the cDNA (Gag, pb0.01; Env,
pb0.01) groups. Serial injections with cAd5/35s failed to
enhance responses to Gag or Env in either the rDNA or the
cDNA group.
Vaccine-induced antibody responses to SIV Gag and HIV Env
Both anti-Gag- and Env-specific IgG responses were detected
after serial inoculations with rDNA-Gag and rDNA-Env
(Fig. 1B). Anti-Gag-specific IgG titers peaked at 16 weeks in
the rDNA group, averaging 123 and at 32 weeks in the prime-
boost group, averaging 155 (Fig. 1B, upper panel). The anti-
Env-specific IgG titers for both the rDNA and the prime-boost
groups peaked at 32 weeks, with titers of 200 and 183,
respectively (Fig. 1B, lower panel). Two serial injections with
rAd5/35-Gag and rAd5/35-Env to the prime-boost group
enhanced both anti-Gag- and anti-Env-specific IgG titers, with
the former increasing from an average of 100 at 150 weeks to an
average of 823 at 154 weeks and the latter increasing from an
average of 74 at 150 weeks to 2240 at 154 weeks. Two serial
injections with rAd5/35-Gag and rAd5/35-Env to the rAd5/35
group generated both anti-Gag- and anti-Env-specific IgG
responses, with the peak titers in the former averaging 335 and
in the latter, 480. Both the anti-Gag- and Env-specific IgG titers
at the time of virus challenge (154 weeks) in the prime-boost
group were significantly higher than those in the rDNA (Gag,
pb0.01; Env, pb0.01) and the cDNA (Gag, pb0.01; Env,
pb0.01) groups. When anti-HIV-89.6-specific neutralization
antibody responses were measured at 154 weeks using the
purified serum IgG, the rDNA, the rAd35 and the prime-boost
groups showed an average neutralization of 4%, 10% and 24%
respectively (data not shown), suggesting that the antibody may
not contribute to the partial protection from virus challenge in
monkeys. Two serial injections with Ad5/35-LacZ had no effect
on anti-Gag and anti-Env IgG responses.
Plasma viral RNA loads and CD4+ T cell counts after
challenge with SHIV
To evaluate the efficacy of a prime-boost vaccine regimen, all
animals received an intravenous challenge with 20 TCID50 of
highly pathogenic SHIV at 154 weeks (Table 1). Peak plasma
RNA loads (Fig. 2A) and rapid or transient CD4+ T cell loss
(Fig. 2B) were observed within 2 weeks after challenge (acute
phase). The cDNA group had the greatest viral RNA loads
(peaking at an average of 4.5×109 copies/ml) and experienced
dramatic loss of CD4+ T cells (≤50 cells/μl). Although its peak
viral RNA loads (an average of 4.9×108 copies/ml) were almost
ten-fold less than those of the cDNA group (pb0.01), the rDNA
group likewise showed reduced CD4+ T cell numbers
Fig. 1. Cellular and humoral responses of vaccinated animals. (A) Freshly isolated PBMC were stimulated with SIV Gag and HIV Env peptides. An ELISPOT assay
was used to monitor the numbers of antigen-specific IFN-γ spot-forming cells. ⁎rDNA vs. prime-boost, pb0.01 (154 weeks). ⁎⁎Prime-boost vs. cDNA, pb0.01
(154 weeks). †rDNA vs. prime-boost group, pb0.01 (155 weeks). (B) End-point Gag- and Env-specific plasma IgG titers were determined in the course of
immunization using ELISA. ⁎rDNA vs. prime-boost, pb0.01 (154 weeks). ⁎⁎Prime-boost vs. cDNA, pb0.01 (154 weeks).
392 K. Someya et al. / Virology 367 (2007) 390–397(≤40 cells/μl, no significance). The prime-boost group showed
greater than 600-fold reduction in peak viral loads and
maintained higher CD4+ T cell numbers compared to the
cDNA group (the peak viral loads of the prime-boost group in
the acute viral phase: an average of 7.3×106 copies/ml,
pb0.01; CD4+ T cell numbers of the prime-boost group: an
average of 616 cells/μl, pb0.01). The initial viremia and
CD4+ T cell numbers in the prime-boost group were also
significantly lower than those in the rDNA group (peak viral
RNA loads, pb0.01; CD4+ T cell numbers, pb0.01). The
rAd5/35 group showed 600-fold reduction in the peak viralloads (an average of 5.3×106 copies/ml) compared to the
cDNA group and maintained higher CD4+ T cell numbers (an
average of 500 cells/μl).
During the set-point phase, the cDNA group showed higher
viral RNA loads (≥5×106 copies/ml) and lower CD4+ T cell
numbers (≤20 cells/μl) (Fig. 2). The set-point viral RNA loads
of the rDNA group (averaging 106 copies/ml) were approxi-
mately five-fold lower than those of the control group, but the
CD4+ T cell numbers recovered by no more than 100 cells/μl.
Two animals (M-5 and M-6) of the prime-boost group showed
well-controlled set-point viral loads and minimal CD4+ T cells
Table 1
Immunization and challenge schedule
Group
(regimen)
Monkey no. Priming immunization
and route
Schedule
(week of priming)
Booster immunization and route Schedule
(week of boosting)
SHIV challenge
rDNA M-1, M-2,
M-3, M-4
rDNA-Gag, 2.5 mg, i.m.
and rDNA-Env, 2.5 mg, i.m.
0, 8, 16 cAd5/35, 2×1011 vp, i.d. 150, 152 20 TCID50, i.v., Week 154
Prime-boost M-5, M-6,
M-7, M-8
rDNA-Gag, 2.5 mg, i.m.
and rDNA-Env, 2.5 mg, i.m.
0, 8, 16 rAD3/35-Gag, 1011 vp, i.d.
and rAD3/35-Env, 1011 vp, i.d.
150, 152 20 TCID50, i.v., Week 154
rAd5/35 M-9, M-10 cDNA, 5 mg, i.m. 0. 8, 16 rAD3/35-Gag, 1011 vp, i.d.
and rAD3/35-Env, 1011 vp, i.d.
150, 152 20 TCID50, i.v., Week 154
cDNA M-11, M-12,
M-13, M-14
cDNA, 5 mg, i.m. 0. 8, 16 cAd5/35, 2×1011 vp, i.d. 150, 152 20 TCID50, i.v., Week 154
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group showed slightly higher viral RNA loads and lower CD4+
T cell numbers. The set-point viral RNA loads for M-6 were
within the detection limit (500 copies/ml) and those for M-5
ranged from b500 to 3×103 copies/ml. The viremia-controlled
M-6 showed more than 800 CD4+ T cells/μl and M-5 showed
600 cells/μl, with the exception of the transient loss (about
350 cells/μl) occurring at 6 and 18 weeks. Set-point viral
RNA loads for both M-7 and M-8 ranged from 3.7×103 to
4.2×104 copies/ml, while CD4+ T cell numbers ranged from
300 to 600 cells/μl. Of the two macaques in the rAd5/35 group,Fig. 2. Plasma viral RNA loads and CD4+ T cell counts after challenge with SHIV. (A
limit of 500 viral RNA copies per ml. ⁎rDNA vs. prime-boost, pb0.01 (acute phase
(acute phase). §rDNAvs. prime-boost, pb0.01 (set-point phase). ¶Prime-boost vs. cD
antibodies. CD4+ T cell numbers were determined using flow cytometry. ⁎rDNA vs
phase). §rDNA vs. prime-boost, pb0.01 (set-point phase). ¶Prime-boost vs. cDNA,one showed enhanced protection, while the other did not. M-9
suppressed viral loads to less than 104 copies/ml and maintained
CD4+ T cell numbers at levels of more than 500 cells/μl. The
viral loads for M-10 ranged from 105 to 106 copies/ml, and its
CD4+ Tcell numbers were less than 300 cells/μl. Throughout the
set-point phase, average plasma viral RNA loads and CD4+ T
cell numbers in the prime-boost group were significantly
different compared to those in the cDNA (plasma viral RNA
loads, pb0.01; CD4+ T cell numbers, pb0.01) and rDNA
(plasma viral RNA loads, pb0.01; CD4+ T cell numbers,
pb0.01) groups.) Plasma RNA copies were determined by quantitative RT-PCR with a detection
). ⁎⁎Prime-boost vs. cDNA, pb0.01 (acute phase). †rDNA vs. cDNA, pb0.01
NA, pb0.01 (set-point phase). (B) Whole blood was stained with CD3 and CD4
. prime-boost, pb0.01 (acute phase). ⁎⁎Prime-boost vs. cDNA, pb0.01 (acute
pb0.01 (set-point phase).
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with SHIV
At an early phase of infection (1 week after challenge), IFN-γ
ELISPOT responses showed that the prime-boost group had
higher numbers of Gag- and Env-specific SFC (Gag specific, an
average of 2385; Env specific, an average of 420) than those of
the rAd5/35 group (Gag specific, an average of 920; Env
specific, an average of 270) (Fig. 2A). Furthermore, lower
numbers of SFC were seen in the rDNA group (an average of
153 SFC specific for Gag; an average of 103 SFC specific for
Env) than those in the prime-boost group (Gag, pb0.01; Env,
pb0.01). The cDNA group showed no responses (≤30 SFC).
Taken together, these results suggest that the prime-boost
regimen elicited the highest frequency of cellular memory T
cells in response to viral challenge.
Discussion
Higher plasma viral RNA loads and lower CD4+ T cell
numbers have been linked to disease progression in HIV-in-
fected individuals (Patke et al., 2002;Mellors et al., 1996, 1997),
suggesting that the generation of robust HIV-specific immunity
may be critical in the control of viral infection. Recently, it was
shown that a recombinant Ad5 vector-based HIV vaccine
induced high levels of cellular immunity and protected animals
from highly pathogenic viral challenge (Shiver et al., 2002). In
contrast, other studies have shown that preexisting anti-Ad5
immunity can attenuate the efficacy of recombinant Ad5-based
HIV vaccine (Barouch et al., 2004; Kostense et al., 2004;
Casimiro et al., 2003). It is essential that such preexisting anti-
Ad5 immunity be overcome if we are to enjoy the benefits
offered by Ad5 as a vaccine vector, such as its induction of
strong T cell immunity. Rare serotype Ad35, which is classified
into subgroup B, has different cell tropism from Ad5 (Marttila et
al., 2005; Segerman et al., 2000; Shayakhmetov et al., 2000; De
Jong et al., 1997), and the seroprevalence of Ad35 in
immunocompromised individuals and those at risk of AIDS
was lower than that of Ad5, suggesting that Ad35 could be used
as the base for an HIV vaccine (Kostense et al., 2004; Vogels et
al., 2003). Therefore, the advantage of constructing a chimeric
Ad5/35 vaccine is that the vector will retain its infectivity with
less risk of preexisting immunity against the vaccine vector than
that of Ad5-based vaccine. This suggests that the Ad5/35
vaccine would allow the basis for adenoviral vectors to be
broadened with improved properties.
In this study, we initially constructed Ad5/35 vector-based
HIV vaccine and demonstrated that its immunogenicity and
protective efficacy in a macaque model. The rAd5/35 vector was
previously developed as a vaccine vehicle for DC targeting (Xin
et al., 2005, 2007; Mizuguchi and Hayakawa, 2002), and the
rAd5/35 vector showed much lower hepatotoxicity than Ad5
(Xin et al., 2005). Recently, Ophorst et al. (2004) reported that
rAd5 vector carrying a part of the fiber molecule of Ad35 (rAd5.
Fib35) was less immunogenic in monkeys than rAd5, and rAd5.
Fib35 showed no significant difference in anti-insert immunity
over Ad5 in mice with high Ad5 vector-specific immunity. Inaddition, Abbink et al. (2007) reported comparative seropreva-
lence and immunogenicity studies involving rAd11, rAd35 and
rAd50 vectors from subgroup B, rAd26, rAd48 and rAd49
vectors from subgroup D and rAd5 vectors from subgroup C.
These rAd vectors were rare serotypes and elicited Gag-specific
cellular immune responses in mice both with and without anti-
Ad5 immunity. However, the rare serotype-based rAd vectors
have proven less immunogenic than rAd5 vectors in animal
models in spite of the absence of anti-Ad5 immunity (Barouch et
al., 2004; Lemckert et al., 2005). In our previous study, rAd5/35
vector was highly immunogenic and significantly less suscep-
tible to preexisting anti-Ad5 immunity than a comparable Ad5
vector (Xin et al., 2005). Although we did not compare the rAd5/
35 vector directly with other serotype rAd vectors, we
demonstrated that the rAd5/35 vector was immunogenic, and a
much higher degree of immunogenicity was achieved by
adopting a prime-boost regimen combining rAd5/35 vectors
with rDNA vaccine in macaques.
To evaluate the efficacy of the vaccine, we monitored T cell
responses, plasma viral RNA loads and CD4+ T cell numbers
following SHIV challenge. In the present study, we used highly
pathogenic SHIV-C2/1 (Shinohara et al., 1998), which
originated from SHIV 89.6 (Lu et al., 1996; Reimann et al.,
1996) because our vaccine regimen was designed to target SIV
Gag and HIV Env antigens and for the virus to well reproduce
high plasma viremia and loss of CD4+ cells (Eda et al., 2006;
Someya et al., 2005, 2006; Ami et al., 2005; Shinohara et al.,
1998).
After challenge with SHIV, all animals in the prime-boost and
the rAd5/35 groups showed high memory T cell responses
against Gag and Env, and these animals showed a reduction in
peak viral RNA loads at the acute phase of infection.
Furthermore, in the set-point phase, two animals in the prime-
boost group and one animal in the rAd5/35 group controlled
SHIV infection, and the remaining two animals in the prime-
boost and one animal in the rAd5/35 groups showed moderate
control. In spite of higher cellular responses being observed in
the prime-boost group than those in the rAd5/35 group, the
difference in protective levels between the prime-boost and the
rAd5/35 groups was not clearly separated. Although it is not
possible to directly compare the levels of immune responses and
protective efficacy induced by the rAd5/35 vector to those of
other rAd vector studies, our results appeared to be similar to
those obtained with the other rAds (Abbink et al., 2007; Barratt-
Boyes et al., 2006; Ophorst et al., 2004; Shiver et al., 2002;
Musey et al., 1997). To clarify the efficacy of the rAd5/35 vector,
further studies to compare with other rAd vectors may be
needed. However, our results suggest that the rAd5/35 vector-
based vaccine either alone or combined with DNA vaccine
elicited a high frequency of viral-specific cellular Tcell response
that may well be key to controlling the acute and chronic phases
of infection.
In conclusion, we have demonstrated that high doses of rAd5/
35 vector-based vaccine afford protective immunity against
SHIV in macaques. Since the rAd5/35 vector-based vaccine can
bypass preexisting anti-Ad5 immunity, therAd5/35-based vac-
cine may offer considerable promise as an HIV vaccine.
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Animals
Fourteen adult cynomolgus macaques (Macaca fascicularis)
were used in this study. The macaques were fed and cared for in
accordance with the standard operating procedure approved by
the Ministry of Education, Culture, Sports, Science and
Technology of Japan. The study was performed in the P3
facility under guidelines established by the laboratory biosafety
manual of World Health Organization (Someya et al., 2005).
Preparation of DNA and recombinant adenoviral vectors
A eukaryotic expression plasmid, pcDNA3.1 (−) (Invitrogen,
Carlsbad, CA), was used as a backbone of the DNAvaccines that
encode the SIVmac239 gag gene (rDNA-Gag) and HIV-1 89.6
env gp160 gene (rDNA-Env), and both DNA vaccines were
constructed as previously described according to the standard
protocol (Someya et al., 2004). The SIVand HIV DNAs for the
DNA vaccines were not modified using humanized codon. No
foreign gene encoding pcDNA 3.1 (−) was used as a control
DNA vaccine (cDNA).
The E1 and E3 regions deleted recombinant Ad5/35 vectors
that encoded the SIVmac239 gag gene (rAd5/35-Gag) and
HIV-1 89.6 env gp160 gene (rAd5/35-Env) were constructed
with an Ad generation kit (Avior Therapeutics, Inc., Seattle,
WA) as previously described (Xin et al., 2005; Mizuguchi and
Hayakawa, 2002). Briefly, SIV gag and HIV env PCR
fragments driven by a CAG promoter were inserted into a
shuttle plasmid, pLHSP (Avior Therapeutics, Inc.), before being
transfected to human embryonic kidney (HEK293) cells. The
recombinant vectors were purified by CsCl gradient centrifuga-
tion, and the total concentration of virus particles was calculated
from the optical density at 260 nm (OD260), using the formula 1
OD260=1×10
12 virus particles/ml.
Immunizations and viral challenge
Four animals of the rDNA group (numbered M-1 through
M-4) received three intramuscular injections of both 2.5 mg of
rDNA-Gag and 2.5mg of rDNA-Env at 8-week intervals (Weeks
0, 8 and 16), followed by two intradermal injections of control
Ad5/35 expressing the gene LacZ (cAd5/35, 2×1011 particles of
each) at 2-week intervals (Weeks 150 and 152). Four animals of
the prime-boost group (numbered M-5 through M-8) received
three injections of both 2.5 mg of rDNA-Gag and 2.5 mg of
rDNA-Env, followed by two injections with both 1011 particles
of rAd5/35-Gag and 1011 particles of rAd5/35-Env. Two animals
of the rAd5/35 group (numbered M-9 and M-10) received three
injections of 5 mg of cDNA, followed by two injections with
both 1011 particles of rAd5/35-Gag and 1011 particles of rAd5/
35-Env. The four control animals of the control group
(numbered M-11 through M-14) received three injections of
5 mg of cDNA, followed by two injections with 2×1011
particles of cAd5/35 (Table 1). All animals received an
intravenous challenge with twenty 50% tissue culture infectiousdoses (TCID50) of highly pathogenic SHIV that originated from
SHIV-89.6 (Someya et al., 2006; Shinohara et al., 1998, Lu et al.,
1996; Reimann et al., 1996) 2 weeks after final immunization (at
154 weeks, Table 1).
Cellular immune response to SIV Gag and HIV Env
The cellular immune responses against SIV Gag and HIV
Env were monitored by IFN-γ ELISPOT assay using
SIVmac239 Gag peptide pools spanning the full length of the
Gag protein and HIV-89.6 Env V3 peptides as previously
described (Someya et al., 2005, 2006). Freshly isolated peri-
pheral blood mononuclear cells were added to 96-well plates in
triplicate at 2×105 cells/well and then incubated for 16 h with
Gag peptide pools or V3 peptide. Individual IFN-γ spot-forming
cells (SFC) were counted by using a KS ELISPOT compact
system (Carl Zeiss, Jena, Germany). An SFC was defined as a
large black spot with a fuzzy border (Mothe et al., 2002).
Antibody responses to SIV Gag and HIV Env
The humoral immune responses were determined by
measuring anti-Gag- and anti-Env-specific IgG titers using
ELISA as previously described (Someya et al., 2005, 2006).
Ninety-six-well ELISA plates were coated with 1 μg/ml of SIV
p27 Gag (Advanced Biotechnologies, Advanced Biotechnolo-
gies, Woburn, MA) or 5 μg/ml of SHIV 89.6P Env peptide
(AIDS Research and Reference Program, National Institutes of
Health, Rockville, MD). Heat-inactivated sera were serially
diluted and then added to the ELISA plate. Anti-Gag- and-Env-
V3-specific IgG bound to the antigens were detected with
alkaline phosphatase-labeled goat anti-monkey IgG (EY
Laboratories, Inc., San Mateo, CA) and p-nitrophenyl-phos-
phate disodium substrate (Invitrogen, Carlsbad, CA).
The SHIV-specific neutralization antibody assay was per-
formed as previously described (Someya et al., 2005, 2006). In
brief, 5 μg/ml of purified serum IgG was incubated with 100
TCID50 of SHIV-C2/1 and then cultured in M8166 cells. The
result was compared with cultures to which preimmune IgG had
been added. Neutralization was expressed as the percent
inhibition of SIV Gag production in the culture supernatant.
The average results+6 SD of serum Ig from normal healthy
monkeys were used as the cutoff for a positive titer (Someya
et al., 2006).
Plasma viral RNA levels and CD4+ T cell counts
SHIV RNA levels in plasma samples were determined by
real-time PCR with a PRISM 7700 sequence detection system
(Perkin-Elmer Applied Biosystems, Forest City, CA) as pre-
viously described (Someya et al., 2006; Sasaki et al., 2002).
All RNA samples were amplified in duplicate. Data were
expressed as RNA copies per milliliter.
CD4+ T cell numbers were measured using a FACS Calibur
flow cytometer system (Becton-Dickinson Bioscience, San Jose,
CA) as previously described (Someya et al., 2006; Yoshino et al.,
2000). Fifty microliters of whole blood specimens was stained
396 K. Someya et al. / Virology 367 (2007) 390–397with anti-human CD3 (clone HIT3a, Becton-Dickinson), anti-
human CD4 (clone SK3 Becton-Dickinson) and anti-human
CD8 (clone SK1, Becton-Dickinson). CD3/CD4 effective T cell
counts were analyzed using Cell Quest software (Becton-
Dickinson).
Statistical analysis
Comparisons of test results among groups of animals were
performed using the Kruskal–Wallis H-test followed by
Student–Newman–Keuls correction.
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